Catamaran Bio to Present Preclinical Data at ASGCT Annual Meeting to Support CAR-NK Approach for Sol

– Two posters describe features of Catamaran’s CAR-NK platform designed to overcome the immunosuppressive effects of the solid tumor microenvironment –CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catamaran Bio, Inc., a biotechnology company developing off‑the-shelf chimeric antigen receptor (CAR)-NK cell therapies to treat ca...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,United States ,Washington ,American ,Mark Boshar ,Linkedin ,American Society Of Gene ,Sv Health Investors ,Catamaran Bio Inc ,Catamaran Bio ,American Society ,Cell Therapy ,Annual Meeting ,Vipin Suri ,Chief Scientific Officer ,Monday May ,Board Number ,Sofinnova Partners ,Lightstone Ventures ,Takeda Ventures ,Astellas Venture Management ,Chief Operating Officer ,